CA2972070C - 5,7-dihydro-pyrrolo-pyridine derivatives - Google Patents

5,7-dihydro-pyrrolo-pyridine derivatives

Info

Publication number
CA2972070C
CA2972070C CA2972070A CA2972070A CA2972070C CA 2972070 C CA2972070 C CA 2972070C CA 2972070 A CA2972070 A CA 2972070A CA 2972070 A CA2972070 A CA 2972070A CA 2972070 C CA2972070 C CA 2972070C
Authority
CA
Canada
Prior art keywords
alkoxy
group
optionally substituted
independently selected
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2972070A
Other languages
English (en)
French (fr)
Other versions
CA2972070A1 (en
Inventor
Lei Zhang
Christopher Ryan BUTLER
Elizabeth Mary Beck
Michael Aaron Brodney
Matthew Frank Brown
Laura Ann Mcallister
Erik Alphie LaChapelle
Adam Matthew Gilbert
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2972070A1 publication Critical patent/CA2972070A1/en
Application granted granted Critical
Publication of CA2972070C publication Critical patent/CA2972070C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2972070A 2016-07-01 2017-06-28 5,7-dihydro-pyrrolo-pyridine derivatives Active CA2972070C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662357624P 2016-07-01 2016-07-01
US62/357,624 2016-07-01
US201662372421P 2016-08-09 2016-08-09
US62/372,421 2016-08-09

Publications (2)

Publication Number Publication Date
CA2972070A1 CA2972070A1 (en) 2018-01-01
CA2972070C true CA2972070C (en) 2026-03-31

Family

ID=59215839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2972070A Active CA2972070C (en) 2016-07-01 2017-06-28 5,7-dihydro-pyrrolo-pyridine derivatives

Country Status (20)

Country Link
US (5) US10604519B2 (enExample)
EP (2) EP3872078A1 (enExample)
JP (1) JP7046018B2 (enExample)
KR (1) KR102470497B1 (enExample)
CN (1) CN109641898B (enExample)
AU (1) AU2017286868B2 (enExample)
CA (1) CA2972070C (enExample)
DK (1) DK3478679T3 (enExample)
ES (1) ES2878160T3 (enExample)
HU (1) HUE054857T2 (enExample)
IL (1) IL263912B (enExample)
MX (1) MX386258B (enExample)
PH (1) PH12019500004A1 (enExample)
PL (1) PL3478679T3 (enExample)
PT (1) PT3478679T (enExample)
SG (1) SG11201811712QA (enExample)
TW (1) TWI736642B (enExample)
UY (1) UY37311A (enExample)
WO (1) WO2018002760A1 (enExample)
ZA (1) ZA201900519B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945771B2 (en) 2017-06-09 2021-03-16 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
FI3642202T3 (fi) * 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114728964A (zh) * 2019-11-22 2022-07-08 豪夫迈·罗氏有限公司 吡咯烷衍生物
AU2021263914B2 (en) * 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
CN112174869B (zh) * 2020-10-12 2023-04-25 蔡霈 N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途
WO2022091048A1 (en) * 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
WO2022235514A1 (en) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
JP2025530462A (ja) * 2022-09-23 2025-09-11 セレベル・セラピューティクス・エル・エル・シー エムラクリジンの結晶形態、その調製方法及びその使用
CN117946113A (zh) * 2022-10-28 2024-04-30 纽欧申医药(上海)有限公司 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
KR20250133677A (ko) * 2022-12-16 2025-09-08 카루나 세러퓨틱스 인코포레이티드 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도
PE20252584A1 (es) * 2022-12-16 2025-11-11 Karuna Therapeutics Inc Compuestos de tetrahidropirrolo-piridinona sustituidos y su uso en el tratamiento de afecciones medicas
JP2026501918A (ja) * 2022-12-16 2026-01-19 カルナ セラピューティクス，インコーポレイテッド 置換ジヒドロピロロ［３，４－ｄ］ピリミジン化合物及び医学的状態の治療におけるその使用
WO2024130064A1 (en) * 2022-12-16 2024-06-20 Karuna Therapeutics, Inc. Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions
WO2024230794A1 (zh) * 2023-05-11 2024-11-14 中国药科大学 氮杂环丁烷衍生物、其制备方法及其医药用途
CN116693437A (zh) * 2023-06-15 2023-09-05 安徽大学 一种N-Boc-3-氮杂环丁烷乙酸的合成方法
KR20260027169A (ko) * 2023-06-20 2026-02-27 하이스코 파마수티컬 그룹 컴퍼니 리미티드 무스카린 m4 수용체 작용제 및 이의 용도
CN121969618A (zh) * 2023-09-13 2026-05-01 中国药科大学 氮杂环丁烷衍生物、其制备方法及其医药用途
CN121925415A (zh) * 2023-09-15 2026-04-24 江苏恩华药业股份有限公司 氮杂环丁烷衍生物、其制备方法及其医药用途
CN122003415A (zh) 2023-10-19 2026-05-08 苏文生命科学有限公司 作为毒蕈碱m4受体正向别构调节剂（m4 pam）的杂芳族化合物
AU2024376208A1 (en) 2023-11-10 2026-04-30 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
CN122249442A (zh) * 2023-11-17 2026-06-19 上海翰森生物医药科技有限公司 杂环羰基类衍生物调节剂、其制备方法和应用
TW202527956A (zh) * 2023-12-07 2025-07-16 美商阿卡蒂亞藥品公司 Ｍ４陽性變構調節劑
WO2025131049A1 (en) * 2023-12-21 2025-06-26 Ignis Therapeutics (Suzhou) Limited Dihydro-pyrrolo-pyridine derivatives and uses thereof
IL328566A (en) 2023-12-22 2026-07-01 Suven Life Sciences Ltd Organic compounds as positive allosteric modulators of the M4 muscarinic receptor (M4 PAMS)
CN122497672A (zh) * 2023-12-27 2026-07-31 宜昌人福药业有限责任公司 一种稠合嘧啶环化合物、药物组合物及其应用
AU2024413926A1 (en) 2023-12-29 2026-07-09 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途
WO2026012503A1 (zh) * 2024-07-12 2026-01-15 海思科医药集团股份有限公司 一种毒蕈碱m4受体激动剂及其用途
WO2026017066A1 (zh) * 2024-07-17 2026-01-22 中国药科大学 取代的氮杂环丁烷衍生物、其制备方法及其医药用途
WO2026017171A1 (zh) * 2024-07-19 2026-01-22 上海翰森生物医药科技有限公司 杂环羰基类衍生物调节剂、其制备方法和应用
WO2026037949A1 (en) 2024-08-15 2026-02-19 Neurosterix Pharma Sàrl 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor
WO2026037961A1 (en) 2024-08-15 2026-02-19 Neurosterix Pharma Sàrl 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor
WO2026047494A1 (en) 2024-08-26 2026-03-05 Suven Life Sciences Limited 2-AMINO-PYRIMIDINE DERIVATIVES AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)
WO2026146402A1 (en) 2024-12-30 2026-07-09 Suven Life Sciences Limited PYRAZOLO AND TRIAZOLOPYRIDINE DERIVATIVES AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
NZ544691A (en) 2000-11-03 2007-12-21 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
AU2003279216A1 (en) 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
BRPI0517438A (pt) 2004-10-25 2008-10-07 Lilly Co Eli composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PT1881985E (pt) 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
DK2013208T3 (da) 2006-04-21 2011-08-15 Pfizer Prod Inc Pyridin[3,4-B]pyrazinoner
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CN1869036A (zh) * 2006-06-30 2006-11-29 中国药科大学 7－取代－3－氯吡咯并[3,4－b]吡啶化合物
KR101108109B1 (ko) 2007-01-22 2012-02-06 화이자 프로덕츠 인코포레이티드 치료 화합물의 토실레이트 염 및 이의 약학 조성물
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
US8957062B2 (en) * 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012149540A1 (en) * 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
CA2855009C (en) * 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
US9637498B2 (en) 2013-08-23 2017-05-02 Vanderbilt University Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
RU2685230C2 (ru) 2014-02-06 2019-04-17 Хептарес Терапьютикс Лимитед Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов
CN115068134B (zh) 2014-03-21 2024-11-19 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器

Also Published As

Publication number Publication date
TWI736642B (zh) 2021-08-21
EP3872078A1 (en) 2021-09-01
US10604519B2 (en) 2020-03-31
IL263912B (en) 2022-04-01
PH12019500004A1 (en) 2019-10-21
AU2017286868B2 (en) 2021-11-11
IL263912A (en) 2019-01-31
MX2019000231A (es) 2019-08-29
US20210309659A1 (en) 2021-10-07
ZA201900519B (en) 2022-07-27
UY37311A (es) 2018-01-31
SG11201811712QA (en) 2019-01-30
JP7046018B2 (ja) 2022-04-01
US20200207762A1 (en) 2020-07-02
US20240190869A1 (en) 2024-06-13
ES2878160T3 (es) 2021-11-18
US20230192690A1 (en) 2023-06-22
CA2972070A1 (en) 2018-01-01
US11905284B2 (en) 2024-02-20
DK3478679T3 (da) 2021-06-21
EP3478679B1 (en) 2021-04-21
EP3478679A1 (en) 2019-05-08
BR112018077257A2 (pt) 2019-04-02
CN109641898A (zh) 2019-04-16
PT3478679T (pt) 2021-06-30
MX386258B (es) 2025-03-18
KR20190035713A (ko) 2019-04-03
WO2018002760A1 (en) 2018-01-04
PL3478679T3 (pl) 2021-10-25
TW201811780A (zh) 2018-04-01
US20180002331A1 (en) 2018-01-04
HUE054857T2 (hu) 2021-10-28
KR102470497B1 (ko) 2022-11-23
JP2019519583A (ja) 2019-07-11
CN109641898B (zh) 2022-04-08
AU2017286868A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
CA2972070A1 (en) 5,7-dihydro-pyrrolo-pyridine derivatives
EP2751102B1 (en) Compounds and compositions as c-kit kinase inhibitors
CA2845169C (en) Compounds and compositions as c-kit kinase inhibitors
WO2019178079A1 (en) Inhibitors of tyrosine kinase 2 mediated signaling
AU2012302176A1 (en) Compounds and compositions as c-kit kinase inhibitors
AU2016204879A1 (en) CDK Inhibitors
AU2012295802A1 (en) Tricyclic heterocyclic compounds and JAK inhibitors
CA2686707A1 (en) Pyrrolopyrimidin-7-one derivatives and their use as pharmaceuticals
CA2971872A1 (en) Mutant idh1 inhibitors useful for treating cancer
CA2722981A1 (en) Selective ligands for the neuronal nicotinic receptors and uses thereof
CA2910759C (en) Imidazo-triazine derivatives as pde10 inhibitors
WO2016100166A1 (en) SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
KR20220042132A (ko) 2h-이미다졸 유도체 및 질환 치료에서 그의 용도
CA2897459A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2942600A1 (en) N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8h)-yl)-thiazol-4-yl) amides
HK40058715A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders
WO2025147603A1 (en) Thienopyridine compounds and uses thereof
BR112018077257B1 (pt) Compostos derivados de 5,7-di-hidro-pirrolo-piridina, composição farmacêutica e seus usos para o tratamento de doenças neurológicas e neurodegenerativas
BR122024018838A2 (pt) Derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas, composição farmacêutica, kit e seus usos
HK40008377B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK1193820A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193820B (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821A (en) Compounds and compositions as c-kit kinase inhibitors
HK1193821B (en) Compounds and compositions as c-kit kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220628

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240703

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250918

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250918

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260328

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260331

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260511

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260511